期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.643382
关键词
chronic myeloid leukemia; tyrosine-kinase inhibitor; drug therapy; immunotherapy; treatment-free remission
类别
Current treatment modalities for chronic myeloid leukemia (CML) are not curative, necessitating the development of novel strategies. Advances in understanding CML biology have led to the investigation of agents targeting Leukemic Stem Cells (LSCs) and the potential for eradication when used in combination with TKIs. Additionally, emerging immunotherapy approaches are being explored for the control of CML.
Although tyrosine Kinase Inhibitors (TKI) has revolutionized the treatment of chronic myeloid leukemia (CML), patients are not cured with the current therapy modalities. Also, the more recent goal of CML treatment is to induce successful treatment-free remission (TFR) among patients achieving durable deep molecular response (DMR). Together, it is necessary to develop novel, curative treatment strategies. With advancements in understanding the biology of CML, such as dormant Leukemic Stem Cells (LSCs) and impaired immune modulation, a number of agents are now under investigation. This review updates such agents that target LSCs, and together with TKIs, have the potential to eradicate CML. Moreover, we describe the developing immunotherapy for controlling CML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据